Targeted therapy in HER2‑positive breast cancer (Review)

  • Authors:
    • Shu Guang Li
    • Li Li
  • View Affiliations

  • Published online on: April 18, 2013     https://doi.org/10.3892/br.2013.95
  • Pages: 499-505
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Treatment options for breast cancer vary based on tumor surface markers and clinical factors, including cytotoxic chemotherapy, hormonal therapy, biological therapy or a combination thereof. An important molecular determinant of therapy is the human epidermal growth factor receptor 2 (HER2) positivity of the tumor, which has been identified in 20‑25% of breast cancers and is a prognostic marker of poor outcome. The advent of HER2‑targeted therapies has significantly improved the survival of patients with HER2‑positive breast cancer. This review focuses on current HER2‑targeted therapeutic options for patients with HER2‑positive breast cancer, including monoclonal antibodies and tyrosine kinase inhibitors (TKIs).
View References

Related Articles

Journal Cover

July-August 2013
Volume 1 Issue 4

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li SG and Li L: Targeted therapy in HER2‑positive breast cancer (Review). Biomed Rep 1: 499-505, 2013.
APA
Li, S.G., & Li, L. (2013). Targeted therapy in HER2‑positive breast cancer (Review). Biomedical Reports, 1, 499-505. https://doi.org/10.3892/br.2013.95
MLA
Li, S. G., Li, L."Targeted therapy in HER2‑positive breast cancer (Review)". Biomedical Reports 1.4 (2013): 499-505.
Chicago
Li, S. G., Li, L."Targeted therapy in HER2‑positive breast cancer (Review)". Biomedical Reports 1, no. 4 (2013): 499-505. https://doi.org/10.3892/br.2013.95